IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects

Leukemia

Volumn 29, Issue 4, 2015, Pages 939-946

  Liu, Y ^a,b   Wu, Y ^b   Wang, Y ^a   Cai, Y ^a,e   Hu, B ^b   Bao, G ^b   Fang, H ^b   Zhao, L ^b   Ma, S ^b   Cheng, Q ^b   Song, Y ^b   Zhu, Z ^a   Chang, H ^a   Yu, X ^b   Sun, A ^a   Zhang, Y ^c   Vignali, D A A ^d,f   Wu, D ^a   Liu, H ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e NANTONG UNIVERSITY   (China)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 35; INTERLEUKIN 6; PLASMID DNA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; IL10 PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; INTERLEUKIN-35, MOUSE; TUMOR NECROSIS FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOIMMUNITY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELLULAR SECRETION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HISTOLOGY; HYDRODYNAMICS BASED TRANSFECTION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SURVIVAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT RESPONSE; ACUTE DISEASE; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; LEUKEMIA; LYMPHOCYTE ACTIVATION; PATHOLOGY; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ANIMALS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-23; INTERLEUKIN-6; INTERLEUKINS; LEUKEMIA; LYMPHOCYTE ACTIVATION; MALE; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927693069     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.310     Document Type: Article

References (40)

1. Blazar BR, Murphy WJ. Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philos Trans R Soc Lond B Biol Sci 2005; 360: 1747-1767.
2. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43: 3-10.
3. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340-352.
4. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 253-257.
5. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004; 114: 1198-1208.
6. Shevach EM. From vanilla to 28 flavors: Multiple varieties of T regulatory cells. Immunity 2006; 25: 195-201.
7. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001; 193: 1311-1318.
8. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-352.
9. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immuno-regulatory T Cells: New therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401-406.
10. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
11. Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant 2002; 8: 525-535.
12. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4 (+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
13. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant2010; 45: 1-11.
14. Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA 1997; 94: 12041-12046.
15. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.
16. Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35-and IL-10-dependent manner. J Immunol 2009; 182: 6121-6128.
17. Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol 2012; 189: 5590-5601.
18. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014; 507: 366-370.
19. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11: 1093-1101.
20. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010; 184: 7144-7153.
21. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007; 37: 3021-3029.
22. Cooke KR1, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996; 88: 3230-3239.
23. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irra-diation and acute graft-versus-host disease: The role of gastrointestinal damageand inflammatory cytokines. Blood 1997; 90: 3204-3213.
24. Cooke KR1, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J Jr. et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 1998; 102: 1882-1891.
25. Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med 2006; 12: 1039-1047.
26. Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol 2012; 189: 464-474.
27. Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, Olver SD et al. Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Blood 2012; 119: 5898-5908.
28. Weston LE, Geczy AF, Briscoe H. Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD. Bone Marrow Transplant 2006; 37: 207-212.
29. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 2011; 34: 566-578.
30. Huber S, Gagliani N, Esplugues E, O'Connor W Jr, Huber FJ, Chaudhry A et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 2011; 34: 554-565.
31. Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 2008; 112: 2101-2110.
32. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009; 113: 945-952.
33. Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C et al. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: 170-178.
34. Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P, Andre V et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 2009; 88: 1261-1272.
35. Zhao XY, Xu LL, Lu SY, Huang XJ. IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur J Immunol 2011; 41: 514-526.
36. Ratajczak P, Janin A, Peffault De Latour R, Leboeuf C, Desveaux A, Keyvanfar K et al. Th17/Treg ratio in human graft-versus-host disease. Blood 2010; 116: 1165-1171.
37. Bahr F, Wehner R, Platzbecker U, Wermke M, Shayegi N, Middeke JM et al. Reconstitution of interleukin-17-producing T helper cells after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013; 19: 357-365.
38. Bossard C, Malard F, Arbez J, Chevallier P, Guillaume T, Delaunay J et al. Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. Leukemia 2012; 26: 1471-1474.
39. Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J et al. Increased plasmacytoid dendritic cells and ROR?t-expressing immune effectors in cutaneous acute graft-versus-host disease. J Leukoc Biol 2013; 94: 1337-1343.
40. Van Den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2002; 2: 273-281.